Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 9/20 | 0.59 |
| ▸ | RAB9A | P51151 | 8/20 | 0.59 |
| ▸ | GAA | P10253 | 2/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | HTT | P42858 | 1/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.55 |
| ▸ | NPC1 | O15118 | 7/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.52 |
| ▸ | MEN1 | O00255 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.49 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | RARA | P10276 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2705788 | 0.87 | KDM4E (0.56) | KDM4ERAB9AGAAPOLBHTT | |
| SCHEMBL694852 | 0.87 | ALDH1A1 (0.56) | KDM4ERAB9AGAAALDH1A1NPC1 | |
| SCHEMBL28928759 | 0.86 | ESR1 (0.49) | KDM4ERAB9AGAAPOLBHTT | |
| SCHEMBL6438482 | 0.86 | NR1H4 (0.54) | KDM4ERAB9AGAAALDH1A1NPC1 | |
| SCHEMBL10222539 | 0.85 | ALDH1A1 (0.58) | KDM4ERAB9AHTTALDH1A1NPC1 | |
| SCHEMBL3612395 | 0.85 | MAPT (0.57) | KDM4ERAB9AHTTALDH1A1NPC1 | |
| SCHEMBL1173463 | 0.85 | PRKCZ (0.54) | KDM4ERAB9AGAAHTTALDH1A1 | |
| SCHEMBL5733736 | 0.85 | CDC7 (0.53) | RAB9AALDH1A1NPC1MEN1KMT2A | |
| SCHEMBL18425631 | 0.84 | RAB9A (0.57) | KDM4ERAB9AGAAPOLBALDH1A1 | |
| SCHEMBL204475 | 0.82 | L3MBTL1 (0.57) | KDM4EGAAHTTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090317360-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090317360-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-12-24 | — | — | US | disclosed |
| US-20090317360-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. | 2009-12-24 | — | — | US | disclosed |
| WO-2008154601-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008154601-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | GENELABS TECHNOLOGIES, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090317360-A1 | ANTI-VIRAL INHIBITORS AND METHODS OF USE | ACE, SARS1, ACE2 | KDM4E 2823/4885RAB9A 2336/4885GAA 42/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.